MktsMarkets

Sagimet Biosciences Inc. - Series A
NASDAQ: SGMTKey statistics
SGMT News
Stories mentioning SGMT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 6,995 | 6,734 | 9,730 | 7,248 | 15,342 | 14,216 | 12,653 | 6,313 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 11,713 | 10,765 | 14,334 | 11,925 | 19,865 | 18,195 | 16,902 | 10,589 |
| Operating Income (Loss) | (11,713) | (10,765) | (14,334) | (11,925) | (19,865) | (18,195) | (16,902) | (10,589) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 1,063 | 1,197 | 1,426 | 1,539 | 1,689 | 1,994 | 2,283 | 2,471 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (10,650) | (9,568) | (12,908) | (10,386) | (18,176) | (16,201) | (14,619) | (8,118) |
| Earnings Per Share (Basic) | (0.33) | (0.30) | (0.40) | (0.32) | (0.56) | (0.52) | (0.45) | (0.25) |
| Earnings Per Share (Diluted) | (0.33) | (0.30) | (0.40) | (0.32) | (0.56) | (0.52) | (0.45) | (0.25) |
| Weighted Average Shares Outstanding (Basic) | 32,560 | 32,346 | 32,465 | 32,195 | 32,195 | 31,351 | 32,143 | 31,914 |
| Weighted Average Shares Outstanding (Diluted) | 32,560 | 32,346 | 32,465 | 32,195 | 32,195 | 31,351 | 32,143 | 31,914 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SGMT
Sagimet Biosciences Inc. - Series A (NASDAQ: SGMT) is a stock listed on the Nasdaq Stock Market under the ticker symbol SGMT. It last traded at $10.83 (Nov 9, 2026, 4:00 PM ET), up 9.9% on the day. That gives Sagimet Biosciences Inc. - Series A a market capitalisation of $694.7M.
Over the past 52 weeks SGMT has traded between $4.50 and $11.45.
For the quarter ended Mar 31, 2026 it reported a net loss of $10.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$10.7M |
| Dec 31, 2025 | — | -$9.6M |
| Sep 30, 2025 | — | -$12.9M |
| Jun 30, 2025 | — | -$10.4M |
From Sagimet Biosciences Inc. - Series A’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…